Companies · Biotech / Pharma
BRECKSVILLE · Biotech / Pharma · refined from filed group “Other Health Care”
Diligence memoA one-page analyst read on Pharmacy Specialty Group, LLC — recommendation, valuation, rhythm, risks.→Pharmacy Specialty Group, LLC looks under-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Pharmacy Specialty Group, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Pharmacy Specialty Group, LLC is one of 227 Biotech / Pharma companies tracked from BRECKSVILLE. By capital raised it ranks in the long tail (ahead of 7% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.
Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seed — a round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 7% of sector peers (real $). Modeled value above 27% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #10 of 12.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Orbis Biosciences, Inc | Pre-Seed | $1.2M | $50.4M | 2.81× |
| Nexion Biosciences Inc | Pre-Seed | $814K | $41.6M | 2.32× |
| Synereca Pharmaceuticals, Inc. | Pre-Seed | $900K | $30.7M | 1.71× |
| Novome Biotechnologies, Inc. | Pre-Seed | $536K | $27.4M | 1.53× |
| Continuum Biosciences, Inc. | Pre-Seed | $500K | $25.6M | 1.43× |
| Me Biosciences, Inc. | Pre-Seed | $1.4M | $25.6M | 1.43× |
| Tychon Biosciences LLC | Pre-Seed | $671K | $10.2M | 0.57× |
| Empire Biotechnologies, Inc. | Pre-Seed | $110K | $5.6M | 0.31× |
| Olive Pharmacy, LLC | Pre-Seed | $100K | $5.1M | 0.29× |
| Pharmacy Specialty Group, LLC this company | Pre-Seed | $100K | $5.1M | 0.29× |
| Therapeutic Solutions International, Inc. | Pre-Seed | $200K | $5.1M | 0.29× |
| Gesea Biosciences, Inc. | Pre-Seed | $100K | $5.1M | 0.29× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Pre-Seed | $100K | 2018-08-21 | $556K | $5.1M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Anthony M. Coury | — | — | 2018-08 |
Pharmacy Specialty Group, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Cinder Biological, Inc. | Biotech / Pharma | Pre-Seed | $100K | $5.1M | same sector · same stage |
| Gesea Biosciences, Inc. | Biotech / Pharma | Pre-Seed | $100K | $5.1M | same sector · same stage |
| Olive Pharmacy, LLC | Biotech / Pharma | Pre-Seed | $100K | $5.1M | same sector · same stage |
| Gaingels Orange Grove Bio LLC | Biotech / Pharma | Pre-Seed | $104K | $1.0M | same sector · same stage |
| Empire Biotechnologies, Inc. | Biotech / Pharma | Pre-Seed | $110K | $5.6M | same sector · same stage |
| Gaingels Q Bio LLC | Biotech / Pharma | Pre-Seed | $111K | $596K | same sector · same stage |
| Gaingels Ochre Bio Llc | Biotech / Pharma | Pre-Seed | $122K | $2.6M | same sector · same stage |
| Gaingels Parallel Bio Llc | Biotech / Pharma | Pre-Seed | $127K | $3.0M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Olive Pharmacy, LLC | Biotech / Pharma | Pre-Seed | $5.1M | 86% |
| Pharmajet, Inc. | Biotech / Pharma | Series B | $568.1M | 85% |
| Singular Bio, Inc. | Biotech / Pharma | Series A | $220.3M | 85% |
| Freedom Pharmacy Operations, LLC | Biotech / Pharma | Seed | $35.8M | 84% |
| Galatea Bio, Inc. | Biotech / Pharma | Seed | $16.2M | 84% |
| PharmaWaste Ventures, LLC | Biotech / Pharma | Seed | $3.5M | 83% |
| Definitive Biotechnologies LLC | Biotech / Pharma | Series A | $8.4M | 83% |
| Oncology Health Partners, Llc | Pharma | Series A | $62.5M | 83% |
See where Pharmacy Specialty Group, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Pharmacy Specialty Group, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.